Mitigating prolonged QT interval in cancer nanodrug development for accelerated clinical translation

Amalendu P Ranjan, Anindita Mukerjee, Lawrence Helson

  • 1Department of Molecular Biology & Immunology and Institute for Cancer Research, Graduate School of Biomedical Sciences, University of North Texas Health Science Center, Fort Worth, Texas 76107, USA. jamboor.vishwanatha@unthsc.edu.

Abstract

Insights

A novel hybrid nanocurcumin formulation effectively prevents drug-induced QT prolongation by protecting the hERG channel. This innovation enhances curcumin

Area of Science:

  • Pharmacology
  • Nanotechnology
  • Drug Development

Background:

  • Cardiac toxicity, specifically QT prolongation, is a major cause of drug failure.
  • Curcumin, an anti-tumor agent, is limited by QT prolongation and low bioavailability.
  • Lipid-based formulations may mitigate hERG channel inhibition and QT prolongation.

Purpose of the Study:

  • To develop a novel formulation of curcumin to overcome its limitations.
  • To assess the efficacy of a hybrid nanocurcumin formulation in preventing QT prolongation.
  • To improve curcumin's bioavailability and stability.

Main Methods:

  • Manual patch clamp assay using HEK 293 cells.
  • Evaluation of a lipopolymeric hybrid nanoparticle formulation encapsulating curcumin.
  • Comparison with liposomal curcumin formulation.

Main Results:

  • Hybrid nanocurcumin prevented hERG channel inhibition at therapeutic concentrations.
  • Hybrid nanocurcumin limited inhibition to 24.8% at 18 μM curcumin.
  • Liposomal curcumin showed limited efficacy at higher concentrations.

Conclusions:

  • A lipopolymeric hybrid nanoparticle formulation of curcumin successfully protects against QT prolongation.
  • The formulation enhances curcumin's bioavailability and stability.
  • This approach offers a strategy to rescue potent drugs with QT prolongation liabilities.

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.9K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
820
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.2K